scholarly journals Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review

2014 ◽  
pp. 1223 ◽  
Author(s):  
Claudia Marchetti ◽  
Margherita Giorgini ◽  
Caterina De Medici ◽  
Innocenza Palaia ◽  
Roberta Iadarola ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Recurrent Ovarian Cancer ◽  
Folate Receptors ◽  
Targeted Drug

scholarly journals Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles

Theranostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 778-795 ◽  
Author(s):  
Minati Satpathy ◽  
Liya Wang ◽  
Rafal J. Zielinski ◽  
Weiping Qian ◽  
Y. Andrew Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Image Guided Therapy ◽  
Image Guided ◽  
Theranostic Nanoparticles ◽  
Targeted Drug ◽  
Guided Therapy

Folate-conjugated nanodiamond for tumor-targeted drug delivery

RSC Advances ◽  
2015 ◽  
Vol 5 (101) ◽  
pp. 82711-82716 ◽  
Author(s):  
Yu Dong ◽  
Ruixia Cao ◽  
Yingqi Li ◽  
Zhiqin Wang ◽  
Lin Li ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tumor Cells ◽  
Targeted Drug Delivery ◽  
Normal Cells ◽  
Folate Receptors ◽  
Receptor Mediated Endocytosis ◽  
Targeted Drug

Relying on the role of folate and folate receptors, NPFD nanoparticles tend to selectively discriminate tumor cells from normal cells and enter the cells by clathrin-dependent and receptor-mediated endocytosis.

Targeted drug delivery via folate receptors

2008 ◽  
Vol 5 (3) ◽  
pp. 309-319 ◽  
Author(s):  
Xiaobin Zhao ◽  
Hong Li ◽  
Robert J Lee
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Folate Receptors ◽  
Targeted Drug

scholarly journals Multifunctional Cholesterol-modified Dendrimers for Targeted Drug Delivery to Cancer Cells Expressing Folate Receptors

2018 ◽  
Vol 37 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Fan-Fan Fu ◽  
Ben-Qing Zhou ◽  
Zhi-Jun Ouyang ◽  
Yi-Lun Wu ◽  
Jing-Yi Zhu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Targeted Drug Delivery ◽  
Folate Receptors ◽  
Targeted Drug

scholarly journals A Novel Method of Magnetic Nanoparticles Functionalized with Anti-Folate Receptor Antibody and Methotrexate for Antibody Mediated Targeted Drug Delivery

Molecules ◽  
2022 ◽  
Vol 27 (1) ◽  
pp. 261
Author(s):  
Madeeha Shahzad Lodhi ◽  
Fatima Khalid ◽  
Muhammad Tahir Khan ◽  
Zahoor Qadir Samra ◽  
Shabbir Muhammad ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Magnetic Nanoparticles ◽  
Cancer Cells ◽  
Hela Cells ◽  
Targeted Drug Delivery ◽  
Folate Receptor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Folate Receptors ◽  
Receptor Antibody ◽  
Targeted Drug

Therapeutic effects of anticancer medicines can be improved by targeting the specific receptors on cancer cells. Folate receptor (FR) targeting with antibody (Ab) is an effective tool to deliver anticancer drugs to the cancer cell. In this research project, a novel formulation of targeting drug delivery was designed, and its anticancer effects were analyzed. Folic acid-conjugated magnetic nanoparticles (MNPs) were used for the purification of folate receptors through a novel magnetic affinity purification method. Antibodies against the folate receptors and methotrexate (MTX) were developed and characterized with enzyme-linked immunosorbent assay and Western blot. Targeting nanomedicines (MNP-MTX-FR Ab) were synthesized by engineering the MNP with methotrexate and anti-folate receptor antibody (anti-FR Ab). The cytotoxicity of nanomedicines on HeLa cells was analyzed by calculating the % age cell viability. A fluorescent study was performed with HeLa cells and tumor tissue sections to analyze the binding efficacy and intracellular tracking of synthesized nanomedicines. MNP-MTX-FR Ab demonstrated good cytotoxicity along all the nanocomposites, which confirms that the antibody-coated medicine possesses the potential affinity to destroy cancer cells in the targeted drug delivery process. Immunohistochemical approaches and fluorescent study further confirmed their uptake by FRs on the tumor cells’ surface in antibody-mediated endocytosis. The current approach is a useful addition to targeted drug delivery for better management of cancer therapy along with immunotherapy in the future.

Targeted Drug Delivery via Folate Receptors for the Treatment of Brain Cancer: Can the Promise Deliver?

2017 ◽  
Vol 106 (12) ◽  
pp. 3413-3420 ◽  
Author(s):  
Jianfeng Guo ◽  
Michele Schlich ◽  
John F. Cryan ◽  
Caitriona M. O'Driscoll
Keyword(s):  
Drug Delivery ◽  
Brain Cancer ◽  
Targeted Drug Delivery ◽  
Folate Receptors ◽  
Targeted Drug
Sign in / Sign up

Export Citation Format

Share Document